secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001104659-23-029038
Event type: other
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharmaceuticals amends bylaws to adopt universal proxy rules, update DGCL provisions, add forum selection clause
--------------------------------------------------------------------------------

- Board approved Second Amended and Restated Bylaws effective Feb 28, 2023, incorporating universal proxy rules and recent DGCL amendments.
- Quorum for stockholder meetings (other than Board-called) changed to majority of voting power; stockholder list requirement removed.
- Enhanced disclosure and procedural requirements for stockholder proposals and director nominations, including universal proxy compliance.
- Indemnification provisions updated with mandatory advancement of expenses subject to Board consent; forum selection clause added for Delaware and federal courts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000110465923029038/0001104659-23-029038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000110465923029038/tm238560d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-029038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer